Zafgen Inc. (Nasdaq: ZFGN) will discontinue the development of its obesity treatment beloranib and cut its workforce by 34% sending the stock price plummeting $3.51 to close at $3.24.
Zafgen discontinues beloranib
July 20, 2016 at 19:04 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.